A
Andrew A. Wolff
Researcher at University of California, San Francisco
Publications - 70
Citations - 3742
Andrew A. Wolff is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Heart failure & Ranolazine. The author has an hindex of 24, co-authored 67 publications receiving 3459 citations. Previous affiliations of Andrew A. Wolff include University of Chicago.
Papers
More filters
Journal ArticleDOI
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Bernard R. Chaitman,Carl J. Pepine,John O. Parker,Jaroslav Skopal,Galina Chumakova,Jerzy Kuch,Whedy Wang,Sandra L. Skettino,Andrew A. Wolff +8 more
TL;DR: Twice-daily doses of ranolazine increased exercise capacity and provided additional antianginal relief to symptomatic patients with severe chronic angina taking standard doses of atenolol, amlodipine, or diltiazem, without evident adverse, long-term survival consequences.
Journal ArticleDOI
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
Bernard R. Chaitman,Sandra L. Skettino,John O. Parker,Peter C. Hanley,Jaroslav Meluzín,Jerzy Kuch,Carl J. Pepine,Whedy Wang,Jeanenne J. Nelson,David Hebert,Andrew A. Wolff,Marisa Investigators +11 more
TL;DR: In chronic angina patients, ranolazine monotherapy was well tolerated and increased exercise performance throughout its dosing interval at all doses studied without clinically meaningful hemodynamic effects.
Journal ArticleDOI
Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial
David A. Morrow,Benjamin M. Scirica,Ewa Karwatowska-Prokopczuk,Sabina A. Murphy,Andrzej Budaj,Sergei Varshavsky,Andrew A. Wolff,Allan M. Skene,Carolyn H. McCabe,Eugene Braunwald +9 more
TL;DR: A randomized, double-blind, placebo-controlled, multinational clinical trial of 6560 patients within 48 hours of ischemic symptoms who were treated with ranolazine (initiated intravenously and followed by runningolazine extended-release 1000 mg twice daily, n = 3279) or matching placebo (n = 3281) was conducted in this paper.
Journal ArticleDOI
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
John G.F. Cleland,John R. Teerlink,Roxy Senior,Evgeny M. Nifontov,John Murray,Chim C. Lang,Vitaly A. Tsyrlin,Barry H. Greenberg,Jamil Mayet,Darrel P. Francis,Tamaz Shaburishvili,Mark J. Monaghan,Mitchell T. Saltzberg,Ludwig Neyses,Scott M. Wasserman,Jacqueline H. Lee,Khalil G. Saikali,Cyril P. Clarke,Jonathan H. Goldman,Andrew A. Wolff,Fady I. Malik +20 more
TL;DR: Omecamtiv mecarbil improved cardiac function in patients with heart failure caused by left ventricular dysfunction and could be the first in class of a new therapeutic agent.
Journal ArticleDOI
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink,Cyril P. Clarke,Khalil G. Saikali,Jacqueline H. Lee,Michael M. Chen,Rafael D. Escandon,Lyndsey Elliott,Rachel Bee,Mohammad R. Habibzadeh,Jonathan H. Goldman,Nelson B. Schiller,Fady I. Malik,Andrew A. Wolff +12 more
TL;DR: First-in-man data show highly dose-dependent augmentation of left ventricular systolic function in response to omecamtiv mecarbil and support potential clinical use of the drug in patients with heart failure.